Peptinovo Biopharma: Targeting Tumors with Smarter Chemotherapy Delivery

Crowdfunding Has Never Been This Easy

Invst Guru is your bi-weekly digest that explores the dynamics of equity crowdfunding. Delivered every Wednesday and Sunday, we connect startups with the power of the crowd, providing investors with access to groundbreaking ventures.

In each issue of Invst Guru, we'll spotlight the latest trends, share success stories, and offer insights from industry leaders. We aim to equip you with the knowledge and opportunities to participate effectively in equity crowdfunding, whether you're looking to fund your innovative startup or invest in potential unicorns.

🔬 Deal in Focus: Peptinovo Biopharma

Reimagining Chemotherapy Through Precision Drug Delivery

In the world of cancer treatment, progress often comes at a painful trade-off. Many of the most potent therapies push the limits of what the human body can tolerate. Side effects such as nerve damage, fatigue, immune suppression, and hair loss have long been considered unavoidable consequences of aggressive treatment. These complications don’t just reduce quality of life — they often interrupt or end chemotherapy regimens before the therapy can complete its course.

Peptinovo Biopharma is building a technology to address this challenge. Its platform, known as PALM™, introduces a new method for delivering cancer drugs that seeks to preserve effectiveness while minimizing damage to healthy tissue. Instead of inventing a new compound, Peptinovo is engineering a smarter delivery vehicle. The company’s lead compound packages paclitaxel, a well-established chemotherapy agent, into a targeted system designed to bypass sensitive tissues.

In multiple preclinical studies, PALM™ has shown potential to concentrate the drug inside tumor cells while reducing exposure to nerves and immune-related organs. If this targeting mechanism continues to perform as expected, it could support chemotherapy regimens that are both more tolerable and more effective.

Peptinovo is currently preparing for its first-in-human trials of PNB-281, its paclitaxel-loaded formulation. The company is raising capital through a Regulation Crowdfunding (Reg CF) offering to fund its next phase of development.

👉 Explore the Offering →

🎯 The Problem at the Center of Modern Chemotherapy

Paclitaxel is a frontline treatment in breast, ovarian, lung, and pancreatic cancers. Its efficacy is well established — but so are its side effects. Peripheral neuropathy, for instance, affects up to 60% of patients treated with paclitaxel, often causing pain and functional impairment that can last long after treatment ends.

The cumulative toxicities of standard chemotherapy regimens force many patients to stop treatment prematurely. These early terminations can undermine efficacy, reduce survival, and increase the emotional and physical toll of cancer therapy. For oncologists and patients alike, finding a way to minimize off-target damage without sacrificing tumor suppression is an urgent priority.

🔬 PALM™: A New Kind of Trojan Horse

Peptinovo’s PALM™ platform (Peptide-Amphiphile Lipid Micelle) mimics the properties of high-density lipoproteins (HDL), the particles responsible for transporting “good” cholesterol in the body. Many tumor types overexpress a receptor called SRB1, which enables them to scavenge HDL as a source of growth.

PALM™ is designed to exploit this vulnerability. By mimicking HDL, it gains access to the SRB1 receptors that line tumor cells, effectively hitching a ride into cancer’s front door. Once internalized, the micelle structure releases its chemotherapy payload in an enzymatically activated form, targeting the tumor while bypassing tissues that lack SRB1.

In preclinical models, this mechanism has consistently demonstrated tumor suppression and a reduced incidence of nerve and immune damage. PALM has been evaluated against more than 60 cancer cell lines by the National Cancer Institute, demonstrating vigorous activity in triple-negative breast cancer models.

📈 Market Potential: Addressing a Multibillion-Dollar Need

Paclitaxel generates over $7 billion in annual global drug sales. Peptinovo’s lead formulation, PNB-281, is specifically aimed at ovarian cancer, a market valued at approximately $145 million in the U.S. alone. Beyond that, the PALM™ delivery system may be adaptable to other chemotherapies and treatment modalities.

The company has developed five additional PALM™-based candidates using different approved chemotherapies. This modular structure can support future product lines, licensing deals, or clinical partnerships, contingent upon continued development and regulatory progress.

🧪 Preclinical Results: Tumor Suppression Without the Trade-Offs

In animal models of ovarian cancer, PNB-281 delivered tumor suppression similar to generic paclitaxel, but did so at lower doses and without the same neurotoxic effects. Higher doses of PALM™-delivered paclitaxel maintained efficacy while continuing to avoid common toxicities.

Toxicology studies in rats showed no signs of neurotoxicity at doses up to five times greater than the maximum tolerated dose of Abraxane®, another paclitaxel formulation. These findings suggest the possibility of more aggressive treatment strategies with reduced patient burden.

Forward-looking statements about Peptinovo’s future development are based on current expectations and subject to risks and uncertainties. Actual results may differ materially. Investors should refer to the offering documents for complete disclosures.

🧬 Founder Insight: From Cardiovascular Science to Oncology

Peptinovo was founded by Ren Homan, a serial biotech entrepreneur whose previous company, AlphaCore, pioneered HDL-based therapies for heart disease before being acquired by AstraZeneca. Drawing from his background in lipid biology, Homan envisioned a way to repurpose HDL-mimicking nanostructures for cancer drug delivery.

Homan’s unique perspective helped launch Peptinovo’s approach: rather than create entirely new drugs, build a superior delivery system that makes existing ones safer and more effective.

🚀 Development Path and Milestones

Peptinovo has completed several key milestones, including:

• Validated PALM™'s mechanism in 60+ cancer models via the National Cancer Institute

• Completed safety and efficacy preclinical trials in rodents

• Raised $8.5M from Cantilever Investors

• Developed multiple drug candidates on the PALM™ platform

• Built proprietary lab infrastructure to support GMP manufacturing

The company anticipates launching its first-in-human trial in the next 12 months to evaluate safety, pharmacokinetics, and early signs of efficacy.

Forward-looking statements about clinical milestones are based on current expectations and assumptions. There is no guarantee of regulatory clearance or trial success.

🤝 Competitive Positioning

The oncology delivery space includes liposomal drugs and antibody-drug conjugates (ADCs), but Peptinovo’s HDL-mimetic particles present a novel alternative. PALM™ is smaller than many current systems and leverages natural cholesterol pathways instead of relying on antibodies or synthetic encapsulants.

Key differentiators include:

• High receptor specificity for SRB1, abundant in solid tumors

• Lack of SRB1 in bone marrow and nerve cells — a natural safety filter

• Scalability for multiple drug pairings

• Potential combination use with checkpoint inhibitors or immunotherapies

🌐 Why It Matters

Cancer survival rates have improved over time, but treatment toxicity remains a significant barrier to quality of life and therapeutic success. Peptinovo’s approach aims to reduce this toxicity burden while preserving, or potentially enhancing, clinical effectiveness.

By targeting the delivery process rather than the drug itself, Peptinovo introduces a pathway to more brilliant, more tolerable treatment regimens.

📎 Learn More

To explore Peptinovo’s live Reg CF campaign and access the official offering documents, visit their portal page:
👉 https://peptinovo.sppx.io/

🧾 Required Disclaimers

Editor’s Note: This article is for informational purposes only. Invst Guru is not affiliated with Peptinovo Biopharma, the offering platform, or any broker-dealer. This content does not constitute investment advice or a solicitation to invest.

Securities Disclaimer: Peptinovo Biopharma is conducting an offering under Regulation Crowdfunding. All investments must be made through a registered funding portal. For full offering details, risks, and disclosures, visit: https://hi.switchy.io/PeptinovoJULY25

Forward-Looking Statement Disclaimer: Forward-looking statements about Peptinovo’s future plans, trials, or commercial outcomes are based on current expectations and assumptions. Actual results may differ materially due to regulatory, scientific, and market risks. Investors should review the company’s official offering documents.

Risk Notice: Investments in startups and private placements involve significant risk, including the potential loss of your entire investment. These securities are illiquid, speculative, and may have long holding periods. Please consult a licensed advisor before investing.

Become a paying subscriber to get access to this post and other subscriber-only content.

Already a paying subscriber? Sign In.

The Signals. The Stories. The Startup Intel You Won’t Find Elsewhere.:

• • 1 just-launched Reg CF, Reg A, or Reg D campaign
• • 1 closing-soon raise — with momentum, context, and caveats
• • Clear breakdowns, red flags, standout metrics
• • No hype. Just the info serious investors want